Form 4 for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-12-08 00:00:00 ET · period of report 2023-12-06 · accession 0001209191-23-057972 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-08 | 2023-12-06 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 851.2K | +4% | +$77.5K |
| D | 2023-12-08 | 2023-12-06 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 819.9K | -1% | $0 |
| D | 2023-12-08 | 2023-12-06 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.49 | -59.8K | 791.3K | -7% | -$448.1K |
| D | 2023-12-08 | 2023-12-06 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 829.9K | +1% | $0 |
| D | 2023-12-08 | 2023-12-06 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | -10.0K | 6.49M | -0.2% | $0 |
| D | 2023-12-08 | 2023-12-06 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $0.00 | -31.2K | 406.2K | -7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-12-06 | M | A | 31,250 | $2.48 | 851,157 | D | — | — | |
| 2 | Common | Class A Common Stock | 2023-12-06 | G | D | 10,000 | $0.00 | 819,907 | D | — | — | |
| 3 | Common | Class A Common Stock | 2023-12-06 | S | D | 59,829 | $7.49 | 791,328 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $7.21 to $8.05. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 4 | Common | Class A Common Stock | 2023-12-06 | C | A | 10,000 | $0.00 | 829,907 | D | — | — | |
| 5 | Derivative | Class B Common Stock | 2023-12-06 | C | D | 10,000 | $0.00 | 6,491,496 | D | $0.00 · — to — | 10,000 Class A Common Stock | (F7) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. |
| 6 | Derivative | Stock Option (Right to Buy) | 2023-12-06 | M | D | 31,250 | $0.00 | 406,250 | D | $2.48 · — to 2030-12-30 | 31,250 Class A Common Stock | (F6) The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter. |